logo
Reishi™ Enters a New Era of Interior Design with Its First Industrial Collaboration with Ligne Roset

Reishi™ Enters a New Era of Interior Design with Its First Industrial Collaboration with Ligne Roset

The MycoWorks Scalable Biomaterial Proves Its Exceptional Performance and Aesthetic Potential in High-End Furniture
PARIS, April 4, 2025 /PRNewswire/ -- Reishi™, the groundbreaking biomaterial developed by MycoWorks, is making a bold statement in the world of interior design. On April 3rd, during the Onirium event at the Palais de Tokyo in Paris, Ligne Roset unveils the Kobold sofa designed by Erwan Bouroullec, marking the first large-scale integration of Reishi™ in luxury furniture. This milestone demonstrates that Reishi™ is no longer an experimental possibility—it is a ready, industrialized solution capable of meeting the most demanding standards of design and craftsmanship.
As one of the natural, non-animal materials available at industrial scale, Reishi™ offers a unique blend of performance, durability, and aesthetics, redefining what is possible in sustainable design.
Reishi™: A Game-Changer for the Future of Design
For years, biomaterials have remained on the fringes of design—too delicate, too niche, or too limited for industrial application. Reishi™ changes this narrative. Thanks to MycoWorks' patented Fine Mycelium™ technology, Reishi™ is the first biomaterial to deliver both exceptional aesthetics and technical performance at scale.
Chosen by Ligne Roset for the Kobold sofa, Reishi™ meets the rigorous requirements of contemporary furniture production while offering a new sensory and visual experience:
Unparalleled Performance: Resistant to daily wear, Reishi™ combines strength, supple elasticity, and durability—qualities essential for interior applications.
A Living Material: Like the finest natural materials, Reishi™ develops a patina over time, enhancing its beauty while preserving its structural integrity.
A Unique Aesthetic: Each sheet of Reishi™ carries its own distinctive veining and organic patterns, creating designs that are one-of-a-kind—echoing the natural beauty of marble or leather.
Industrial Scalability: Unlike other biomaterials, Reishi™ is available at scale, offering a reliable, sustainable alternative to traditional materials for major design brands.
'At MycoWorks, we believe that art inspires science, and that mycelium can redefine the future of design,' says Sophia Wang, co-founder of MycoWorks. 'The integration of Reishi™ into the Ligne Roset collection is a powerful demonstration that sustainable luxury is not a concept of tomorrow—it is a reality today.'
Beyond Materials: A Vision for Sustainable Interiors
The Kobold sofa Made with Reishi™ — now available, in the Ligne Roset 2025 catalog — is more than a new product. It's a proof of concept that Reishi™ can deliver the performance and beauty needed to redefine sustainable interiors.
'We have been waiting for years for a natural and sustainable material that meets our quality standards and our customers' expectations. Our partnership with MycoWorks strengthens our commitment to ethical and sustainable development, while upholding the highest level of quality for which the Roset Group is known. By embracing innovation, it also offers us the opportunity to redefine the legacy of Made in France design,' says Antoine Roset, Managing Director of Ligne Roset.
Designed by Erwan Bouroullec, the Kobold is a versatile and modular seating solution that seamlessly integrates various functional elements around a central sofa unit. These sustainable features align with the choice of incorporating Reishi™ to make it a piece of design that embodies eco-conscious innovation without compromising on aesthetics, comfort, or longevity.
In the evocative Onirium scenography, lush greenery will envelop the Reishi™ Kobold, symbolizing a new era where nature and design coexist seamlessly. This installation is not just an artistic display—it is an invitation for designers and brands to embrace the future of materials and integrate Reishi™ into their creative visions.
The collaboration with Ligne Roset is the latest step in MycoWorks' mission to provide scalable, sustainable materials that meet the highest standards of luxury. With Reishi™, brands can move beyond imitation leather toward a new category of natural materials that are both performative and aesthetic.
About Ligne Roset
Renowned for its remarkable collaborations with both established talents and emerging voices in contemporary design, Ligne Roset offers its clients a comprehensive lifestyle experience, blending boldness and aesthetics through its collections of furniture, accessories, lighting, rugs, textiles, and other complementary objects.
With a commitment to in-house manufacturing, Ligne Roset rigorously controls every step of the product creation process, ensuring the highest standards of production.
Driven by a profound belief in design, as demonstrated by its ongoing investment and innovation strategy, Ligne Roset has grown from a small French design house to a multinational company, operating several factories and a headquarters in France, with over 200 Ligne Roset stores and 1,000 distributors worldwide. The company has remained family-owned since its founding in 1860.
For more information, visit ligne-roset.com.
About Erwan Bouroullec
A distinguished French designer, Erwan Bouroullec is a creator with an unbound soul who continues to forge his path with subtle elegance. His creations perfectly embody his passion for functional simplicity and his deep respect for nature, values that shine through in his projects, whether they involve architecture, furniture, or unexpected collaborations.
A graduate of the École Nationale Supérieure d'Arts de Paris-Cergy in 1998, Erwan Bouroullec currently runs a studio in Paris and a workspace in Burgundy.
For more information, visit erwanbouroullec.com.
About Reishi by MycoWorks
In 2013, artists Philip Ross and Sophia Wang founded MycoWorks, a biotechnology dedicated to growing the future of materials. MycoWorks' patented Fine Mycelium™ platform engineers mycelium as it grows, crafting biomaterials of unparalleled strength, durability, and hand-feel. Thirty years of savoir-faire have led to Reishi™ – a new category of materials crafted from mycelium, the roots structure of fungi. Each sheet of Reishi™ carries a singular imprint of nature's unique craftsmanship, seamlessly intertwining art and design with the utmost respect for the natural world. For more information please visit mycoworks.com and follow @madewithreishi on Instagram.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information
Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information

Yahoo

time35 minutes ago

  • Yahoo

Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information

ARLINGTON, Va., June 13, 2025 /PRNewswire/ -- Kalorama Information, a leading publisher of life sciences market research, has released the highly anticipated third edition of its landmark report, Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025. This comprehensive analysis offers an in-depth look at the financial ecosystem fueling the explosive growth of the cell and gene therapy (CGT) industry — a market defined by breakthrough innovation, global competition, and evolving funding landscapes. The report is released in two installments, with the first part available now, covering deals through Q4 2024. The second installment, included with purchase, will be released in Fall 2025 and cover activity through Q3 2025. "Many categories of deals, such as collaborations, distribution/co-marketing, and manufacturing/supply chain, have shown a long-term pattern of growth," said Justin Saeks, senior market analyst at Kalorama Information. "And there's reason for optimism regarding continued investments. Cell and gene therapy-related companies have continued to receive huge amounts of investment." Key Insights from the Report: Over 2,000 CGT-related deals analyzed, with quarterly trends tracked from Q1 2021 to Q4 2024 Despite a tighter funding environment, 2024 investment reached an estimated $39 billion, with a sharp Q4 uptick Top dealmakers include Astellas, Bristol Myers Squibb, Ginkgo Bioworks, Charles River, and Eli Lilly Deal types covered: VC/PE, IPO/SPAC, licensing, tech transfer, acquisitions, supply chain partnerships, and more Global perspective includes detailed breakdowns by region — North America, Europe, and APAC Why This Matters Now The CGT market is maturing fast, with fluctuating investment trends, growing deal diversity, and strategic partnerships becoming essential to survival. In 2023 and 2024, firms faced a contraction in available capital — from $73 billion in 2021 down to $35 billion in 2023 — yet collaborative and manufacturing partnerships have been on the rise. This suggests that dealmaking is evolving, not disappearing. Who Should Purchase and Read This Report This report is essential for: Biotech and pharma execs seeking M&A or licensing opportunities VC/PE investors tracking funding cycles and active biotech targets Strategic planners and BD professionals looking to benchmark activity Consultants, CROs, and CMOs aligning services with market needs Regulatory and policy advisors assessing funding shifts and regional dynamics Strategic Use Cases Identify high-activity players and ideal partners for collaboration or acquisition Benchmark funding rounds and valuations for startups or expanding companies Inform R&D focus by tracking which technologies (e.g., CRISPR, AAV) are attracting deals Support global expansion using regional deal patterns and emerging market trends Strengthen regulatory preparedness by understanding the impact of policy shifts on financing Companion Report Available This report pairs with Kalorama's Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 2024–2030 (4th Edition) — offering disease-area breakdowns of the CGT landscape in oncology, neurology, musculoskeletal, and beyond. Get the Report Download or purchase the report here:Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025 (3rd Edition) Explore the companion report:Cell and Gene Therapy Market Dynamics by Disease Type, 2024–2030 (4th Edition) About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a trusted source of market research in the life sciences. With a focus on in vitro diagnostics, biotechnology, and medical devices, Kalorama reports are used by top healthcare companies, government agencies, and investment firms worldwide. For purchase or custom consultation, contact:Sheri DavieKalorama Information Sales For media inquiries please contact:Alisa AlvichMarketing View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®
Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®

Yahoo

time43 minutes ago

  • Yahoo

Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®

BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture and factory automation markets, is proud to announce the certification of the Memor 17 Healthcare mobile computer with OncoSafety Remote Control®, the advanced oncology workflow solution developed by B. Braun, a global leader in smart infusion therapy and healthcare technology. This integration combines Datalogic's most advanced healthcare-grade mobile computer with B. Braun's OncoSafety Remote Control®, enabling unmatched traceability, medication accuracy, and compliance in oncology treatment. Together, these technologies deliver a safer, more efficient experience for healthcare professionals and patients alike. Designed for front-line healthcare, the Memor 17 Healthcare features 5G connectivity, Wi-Fi 6E, and an ultra-rugged, disinfectant-ready design. The integrated Halogen™ 2121DL scan engine ensures fast and accurate barcode capture – even on damaged or poorly printed labels – while Datalogic's signature Green Spot technology provides silent scan confirmation, ideal for quiet zones such as neonatal wards or intensive care units. The certification with OncoSafety Remote Control® extends the capabilities of the Memor 17 Healthcare across oncology workflows – from bedside medication administration to remote patient visits – ensuring the highest standards of patient safety, data access, and workflow efficiency. The Memor 17 Healthcare also supports programmable emergency alerts and custom gestures, allowing clinical staff to trigger safety protocols instantly. With long-term Android™ support (version 18 and beyond), AI-powered software tools from the Datalogic Mobility Suite, and a slim, ergonomic form factor, this device is ready to meet the evolving needs of healthcare environments. "The Memor 17 Healthcare sets a new benchmark for patient care and safety in oncology," said Rosario Casillo, Data Capture Product and Solutions Executive VP at Datalogic. "Its certification with B. Braun's OncoSafety Remote Control® enables seamless verification of patient-treatment matching with their advanced solution, ensuring healthcare professionals can rely on a connected, secure, and highly functional device to deliver critical care wherever it's needed." "Our mission at B. Braun is to protect and improve the health of people around the world. We are pleased to collaborate with Datalogic to equip caregivers with the technology needed to make well-informed decisions and reduce medication errors," added Thore Heinemann, Senior Digital Solution Manager at B. Braun. Datalogic GroupA global technology leader in the automatic data capture and industrial automation markets since 1972, specializes in the design and production of barcode readers, mobile computers, sensors for detection, measurement and safety, machine vision and laser marking systems. These products and solutions enhance efficiency and quality across the entire value chain, in industries such as retail, manufacturing, transportation and logistics, and healthcare. Trusted by major global players in its four target sectors, Datalogic is recognized for its customer focus and commitment to quality, upheld by the Group for over 50 years. Today, Datalogic Group, headquartered in Bologna (Italy), employs approximately 2,700 staff worldwide, distributed in 27 countries, with 10 manufacturing and repair facilities in the U.S.A., Hungary, Slovakia, Italy, China, and Vietnam, 10 Research & Development centers and 3 DL Labs in Italy, U.S.A., Vietnam, and Czech Republic. In 2024, Datalogic Group recorded sales of € 493.8 million and invested € 65.9 million in R&D. Datalogic S.p.A. has been listed in the Euronext STAR Milan segment of the Italian Stock Exchange since 2001 as Visit Datalogic and the Datalogic logo are registered trademarks of Datalogic S.p.A. in many countries, including the U.S.A. and the E.U. Other trademarks belong to their respective owners. B. Braun B. Braun is one of the world's leading providers and manufacturers of healthcare solutions developing innovative products and services in smart infusion therapy, anesthesia, intensive care, and oncology. Through partnerships and digital technologies like OncoSafety Remote Control®, B. Braun supports safer, more effective clinical outcomes. View original content: SOURCE Datalogic Sign in to access your portfolio

Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information
Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information

Yahoo

timean hour ago

  • Yahoo

Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information

ARLINGTON, Va., June 13, 2025 /PRNewswire/ -- Kalorama Information, a leading publisher of life sciences market research, has released the highly anticipated third edition of its landmark report, Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025. This comprehensive analysis offers an in-depth look at the financial ecosystem fueling the explosive growth of the cell and gene therapy (CGT) industry — a market defined by breakthrough innovation, global competition, and evolving funding landscapes. The report is released in two installments, with the first part available now, covering deals through Q4 2024. The second installment, included with purchase, will be released in Fall 2025 and cover activity through Q3 2025. "Many categories of deals, such as collaborations, distribution/co-marketing, and manufacturing/supply chain, have shown a long-term pattern of growth," said Justin Saeks, senior market analyst at Kalorama Information. "And there's reason for optimism regarding continued investments. Cell and gene therapy-related companies have continued to receive huge amounts of investment." Key Insights from the Report: Over 2,000 CGT-related deals analyzed, with quarterly trends tracked from Q1 2021 to Q4 2024 Despite a tighter funding environment, 2024 investment reached an estimated $39 billion, with a sharp Q4 uptick Top dealmakers include Astellas, Bristol Myers Squibb, Ginkgo Bioworks, Charles River, and Eli Lilly Deal types covered: VC/PE, IPO/SPAC, licensing, tech transfer, acquisitions, supply chain partnerships, and more Global perspective includes detailed breakdowns by region — North America, Europe, and APAC Why This Matters Now The CGT market is maturing fast, with fluctuating investment trends, growing deal diversity, and strategic partnerships becoming essential to survival. In 2023 and 2024, firms faced a contraction in available capital — from $73 billion in 2021 down to $35 billion in 2023 — yet collaborative and manufacturing partnerships have been on the rise. This suggests that dealmaking is evolving, not disappearing. Who Should Purchase and Read This Report This report is essential for: Biotech and pharma execs seeking M&A or licensing opportunities VC/PE investors tracking funding cycles and active biotech targets Strategic planners and BD professionals looking to benchmark activity Consultants, CROs, and CMOs aligning services with market needs Regulatory and policy advisors assessing funding shifts and regional dynamics Strategic Use Cases Identify high-activity players and ideal partners for collaboration or acquisition Benchmark funding rounds and valuations for startups or expanding companies Inform R&D focus by tracking which technologies (e.g., CRISPR, AAV) are attracting deals Support global expansion using regional deal patterns and emerging market trends Strengthen regulatory preparedness by understanding the impact of policy shifts on financing Companion Report Available This report pairs with Kalorama's Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 2024–2030 (4th Edition) — offering disease-area breakdowns of the CGT landscape in oncology, neurology, musculoskeletal, and beyond. Get the Report Download or purchase the report here:Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025 (3rd Edition) Explore the companion report:Cell and Gene Therapy Market Dynamics by Disease Type, 2024–2030 (4th Edition) About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a trusted source of market research in the life sciences. With a focus on in vitro diagnostics, biotechnology, and medical devices, Kalorama reports are used by top healthcare companies, government agencies, and investment firms worldwide. For purchase or custom consultation, contact:Sheri DavieKalorama Information Sales For media inquiries please contact:Alisa AlvichMarketing View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store